PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board
Experts in translational oncology and targeted protein degradation join Dr Simon Cook, Dr Lorenz Mayr and Dr Catherine Beech to provide scientific and strategic oversight
PhoreMost reaches milestone in a Target Discovery Alliance with Boehringer Ingelheim
PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
PhoreMost and ThinkCyte collaborate to advance AI based drug discovery
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, today announced a strategic research p
PhoreMost enters multi-target collaboration with targeted protein degradation leader Arvinas
Cambridge, UK - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and…
PhoreMost enters multi-project drug target discovery collaboration with Roche
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes.
PhoreMost promotes Dr Neil Torbett to Chief Executive Officer
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announces the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board.
PhoreMost expands into new facility at Unity Campus, Cambridge
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge.
NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics
NeoCura Bio-Medical Technology Co Ltd, a leading RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, have announced an oncology drug discovery research collaboration.
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies
Cambridge, UK and Durham, NC, USA: PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, today announced a collaboration to study oncology targets currently considered undruggable.
PhoreMost appoints Christian Dillon as Vice President of Biology
PhoreMost Ltd, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has appointed Dr Christian Dillon as Vice President of Biology. In this new role, Dr Dillon will work across all the Company’s areas of interest, including oncology, targeted protein degradation, and neurodegeneration, leading PhoreMost’s efforts to progress the novel…
PhoreMost closes £33M Series B financing
PhoreMost Ltd, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing…
PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and XtalPi Inc., a leading algorithm-driven artificial intelligence (AI)-based pharmaceutical technology company, today announced they have entered into a drug discovery collaboration agreement. Financial details are not disclosed.
PhoreMost strengthens leadership team with two key appointments
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth. Dr Catherine Beech joins the PhoreMost Board as a Non-Executive Director. Dr Benedict (Ben) Cross has joined as Senior Director (Technology), and will direct the…
PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics.
PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.
PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, announces an expansion of its collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.
PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director.
PhoreMost and inStem enter structural biology alliance
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focused collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.
PhoreMost and C4X Discovery announce neurodegeneration focused drug discovery collaboration
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announced they have signed a neurodegeneration drug discovery collaboration agreement. Combining the two companies’ technology platforms to validate novel targets, the initial focus will be on…
Ligand subsidiary Vernalis and PhoreMost announce drug discovery collaboration for novel oncology target
Ligand Pharmaceuticals' subsidiary Vernalis and PhoreMost sign a research collaboration agreement on an undisclosed novel oncology target.
PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programmes
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.
PhoreMost completes £11M ($15M) Series-A round to enter drug discovery
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER®” phenotypic screening platform into first-in-class drug…
Cancer immunotherapy research receives £1m Innovate UK funding
PhoreMost Limited and NeoPhore Limited have announced the companies will receive £1 million of funding to support the development of a novel small-molecule cancer immunotherapy programme, following the award of a Biomedical Catalyst grant in a recent Innovate UK competition.
PhoreMost and Plexxikon collaborate to identify novel drug targets
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.